Daily Stock Opinions and Ratings

Opinions

Benj Gallander Theragenics Corp TGX-N PAST TOP PICK Nov 03, 2011

(A Top Pick Nov 11/10. Up 28.57%.)

Benj Gallander

Owned

Unlock Rating

$1.600

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

PAST TOP PICK

(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.

TOP PICK

They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.

TOP PICK

In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.

PAST TOP PICK

(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.

WEAK BUY

Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.

TOP PICK

Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.

TOP PICK

Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.

PAST TOP PICK

(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.

PAST TOP PICK

(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Brian Madden

First Avenue Investment Counsel

Jim Cramer - Mad Money

CNBC

John Zechner

J. Zechner & Assoc

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Benj Gallander Theragenics Corp TGX-N PAST TOP PICK Nov 03, 2011

You might be interested:

Theragenics Corp(TGX-N)

Theragenics Corp(TGX-N)

Theragenics Corp(TGX-N)

Theragenics Corp(TGX-N)

Theragenics Corp(TGX-N)

Theragenics Corp(TGX-N)

Theragenics Corp(TGX-N)

Theragenics Corp(TGX-N)

Theragenics Corp(TGX-N)

Popular Articles

Most Recent Experts

Larry Berman CFA, CMT, CTA

Brian Madden

Jim Cramer - Mad Money

John Zechner

The Panic-Proof Portfolio (Stockchase Research)